GT Biopharma, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 0.227 million compared to USD 5.44 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 5.1 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.346 USD | +3.63% | +1.38% | -56.27% |
26/03 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01/02 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.27% | 4.46M | |
+30.95% | 695B | |
+26.51% | 568B | |
-4.64% | 361B | |
+19.53% | 330B | |
+3.82% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+8.47% | 168B |
- Stock Market
- Equities
- GTBP Stock
- News GT Biopharma, Inc.
- GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023